AGA1
MCID: ALP061
MIFTS: 54

Alopecia, Androgenetic, 1 (AGA1)

Categories: Rare diseases

Aliases & Classifications for Alopecia, Androgenetic, 1

MalaCards integrated aliases for Alopecia, Androgenetic, 1:

Name: Alopecia, Androgenetic, 1 58 30 13 39 74
Androgenetic Alopecia 58 39 54 26 17 74
Androgenic Alopecia 54 26
Androgenetic Alopecia; Aga 58
Female Pattern Baldness 26
Female Pattern Alopecia 74
Male Pattern Alopecia 26
Male Pattern Baldness 26
Alopecia Androgenetic 56
Pattern Baldness 26
Aga1 58
Aga 58

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant in males
recessive in females


HPO:

33
alopecia, androgenetic, 1:
Inheritance sex-limited autosomal dominant


Classifications:



External Ids:

OMIM 58 109200
MedGen 43 C4049090
SNOMED-CT via HPO 70 278040002 56317004

Summaries for Alopecia, Androgenetic, 1

OMIM : 58 Androgenetic alopecia is characterized by a loss of hair from the scalp that follows a defined pattern (Hamilton, 1951). It occurs in women as well as in men. It is caused by a shortening of the anagen (growth) phase and miniaturization of the hair follicle, which results in the formation of progressively thinner, shorter hair (Bergfeld, 1995). In men, the condition is often referred to as male pattern baldness (MPB) and appears to be androgen-dependent (Hamilton, 1942). The condition is hereditary, and follows a pattern that may be consistent with an autosomal dominant trait (Osborn, 1916). Linkage evidence for an autosomal locus on 3q26 (AGA1) has been identified (Hillmer et al., 2008). See 300710 (AGA2) for a discussion of X linkage of androgenetic alopecia. A third locus has been found on chromosome 20p11 (AGA3; 612421). (109200)

MalaCards based summary : Alopecia, Androgenetic, 1, also known as androgenetic alopecia, is related to androgenic alopecia and prostatic hyperplasia, benign. An important gene associated with Alopecia, Androgenetic, 1 is AFA1 (Alopecia, Androgenetic), and among its related pathways/superpathways are Transcription Androgen Receptor nuclear signaling and Metabolism of steroid hormones. The drugs Finasteride and Minoxidil have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and skin, and related phenotypes are alopecia and endocrine/exocrine gland

Genetics Home Reference : 26 Androgenetic alopecia is a common form of hair loss in both men and women. In men, this condition is also known as male-pattern baldness. Hair is lost in a well-defined pattern, beginning above both temples. Over time, the hairline recedes to form a characteristic "M" shape. Hair also thins at the crown (near the top of the head), often progressing to partial or complete baldness.

NIH Rare Diseases : 54 Androgenetic alopecia is a common form of hair loss in both men and women. In men, hair is usually lost in a well-defined pattern, beginning above both temples and is usually referred to as male-pattern baldness. Over time, the hairline recedes to form a characteristic 'M' shape. Hair also thins near the top of the head, often progressing to partial or complete baldness. The pattern of hair loss in women differs from men (female pattern hair loss). In women, the hair becomes thinner all over the head, and the hairline does not recede. Androgenetic alopecia in women rarely leads to total baldness. A variety of genetic and environmental factors likely play a role in causing this condition. Mutations in the AR gene have also been associated with androgenetic alopecia.

Related Diseases for Alopecia, Androgenetic, 1

Diseases in the Alopecia, Androgenetic, 1 family:

Alopecia, Androgenetic, 2 Alopecia, Androgenetic, 3

Diseases related to Alopecia, Androgenetic, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 154)
# Related Disease Score Top Affiliating Genes
1 androgenic alopecia 33.2 AR CYP19A1 SHBG
2 prostatic hyperplasia, benign 30.2 AR SHBG SRD5A1 SRD5A2
3 hyperandrogenism 30.1 CYP19A1 CYP21A2 SHBG
4 prostate disease 29.8 AR CYP19A1 SRD5A1
5 polycystic ovary syndrome 29.5 CYP19A1 CYP21A2 SHBG SRD5A1
6 prostate cancer 28.8 AR CFLAR CYP19A1 SHBG SRD5A1 SRD5A2
7 aspartylglucosaminuria 12.5
8 alopecia, androgenetic, 2 12.4
9 alopecia, androgenetic, 3 12.4
10 lysosomal storage disease 11.5
11 alopecia 11.4
12 marie unna congenital hypotrichosis 11.4
13 angiokeratoma 11.3
14 hypotrichosis 1 11.3
15 hypotrichosis simplex 11.3
16 fucosidosis 11.2
17 galactosemia 11.2
18 mannosidosis, alpha b, lysosomal 11.2
19 glucocorticoid resistance, generalized 11.2
20 alopecia areata 10.7
21 rapidly involuting congenital hemangioma 10.7
22 diabetes mellitus, noninsulin-dependent 10.5
23 telogen effluvium 10.5
24 prostate cancer, hereditary, 8 10.5
25 prostate cancer, hereditary, 6 10.5
26 neurofibromatosis, type ii 10.3
27 prostatic adenoma 10.3
28 lichen planopilaris 10.3
29 arteries, anomalies of 10.3
30 pityriasis rubra pilaris 10.3
31 coronary artery anomaly 10.3
32 sexual disorder 10.3
33 diffuse alopecia areata 10.3
34 heart disease 10.3
35 frontal fibrosing alopecia 10.3
36 hermaphroditism 10.2 AR SRD5A2
37 47, xxy 10.2 AR SHBG
38 postmenopausal atrophic vaginitis 10.2 AR SHBG
39 neutrophil migration 10.2
40 coronary heart disease 1 10.2
41 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 10.2
42 dermatitis 10.2
43 psoriasis 10.2
44 depression 10.2
45 hypoactive sexual desire disorder 10.2 CYP19A1 SHBG
46 irritable bowel syndrome 10.1
47 gender identity disorder 10.1 AR CYP19A1
48 sebaceous gland disease 10.1 AR SHBG
49 5-alpha reductase deficiency 10.1 SRD5A1 SRD5A2
50 estrogen excess 10.1 CYP19A1 SHBG

Graphical network of the top 20 diseases related to Alopecia, Androgenetic, 1:



Diseases related to Alopecia, Androgenetic, 1

Symptoms & Phenotypes for Alopecia, Androgenetic, 1

Human phenotypes related to Alopecia, Androgenetic, 1:

33
# Description HPO Frequency HPO Source Accession
1 alopecia 33 HP:0001596

Symptoms via clinical synopsis from OMIM:

58
Hair:
early baldness

Clinical features from OMIM:

109200

MGI Mouse Phenotypes related to Alopecia, Androgenetic, 1:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.17 AR CFLAR CYP19A1 SRD5A1 SRD5A2 TGFB2

Drugs & Therapeutics for Alopecia, Androgenetic, 1

Drugs for Alopecia, Androgenetic, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Finasteride Approved Phase 4,Phase 3,Phase 1,Phase 2 98319-26-7 57363
2
Minoxidil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 38304-91-5 4201
3
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
4 Hormones Phase 4,Phase 3,Phase 1,Phase 2
5 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
6 Antihypertensive Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
7 5-alpha Reductase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
8 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
9 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
10 Vasodilator Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
11 Mineralocorticoids Phase 4
12 Natriuretic Agents Phase 4
13 Diuretics, Potassium Sparing Phase 4
14 Mineralocorticoid Receptor Antagonists Phase 4
15 diuretics Phase 4
16
Dutasteride Approved, Investigational Phase 3,Phase 1 164656-23-9 6918296 152945
17 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18
Nitric Oxide Approved Phase 1, Phase 2 10102-43-9 145068
19
Acetylcholine Approved, Investigational Phase 2 51-84-3 187
20
Bimatoprost Approved, Investigational Phase 2,Phase 1 155206-00-1 5311027
21
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
22
Vitamin C Approved, Nutraceutical Phase 1, Phase 2,Phase 2 50-81-7 54670067 5785
23
Maleic acid Experimental, Investigational Phase 1, Phase 2 110-17-8, 110-16-7 444972
24 HIV Protease Inhibitors Phase 2
25
protease inhibitors Phase 2
26 Proteasome Inhibitors Phase 2
27 Radiation-Protective Agents Phase 2
28 Protective Agents Phase 2,Phase 1
29 Ammonium trichloro(dioxoethylene-O,O'-)tellurate Phase 2
30 Antiviral Agents Phase 2
31 Anti-Infective Agents Phase 2,Not Applicable
32 Immunologic Factors Phase 2
33 Adjuvants, Immunologic Phase 2
34 Free Radical Scavengers Phase 1, Phase 2
35 Anti-Asthmatic Agents Phase 1, Phase 2
36 Bronchodilator Agents Phase 1, Phase 2
37 Peripheral Nervous System Agents Phase 1, Phase 2
38 Autonomic Agents Phase 1, Phase 2
39 Antioxidants Phase 1, Phase 2
40 Neurotransmitter Agents Phase 1, Phase 2,Phase 2
41 Respiratory System Agents Phase 1, Phase 2
42 Endothelium-Dependent Relaxing Factors Phase 1, Phase 2
43 Mitogens Phase 1, Phase 2,Not Applicable
44 Androgens Phase 2,Phase 1
45 Cholinergic Agents Phase 2
46 abobotulinumtoxinA Phase 2
47 Acetylcholine Release Inhibitors Phase 2
48 Botulinum Toxins Phase 2
49 Botulinum Toxins, Type A Phase 2
50 Ophthalmic Solutions Phase 2

Interventional clinical trials:

(show top 50) (show all 117)
# Name Status NCT ID Phase Drugs
1 Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Unknown status NCT02999737 Phase 4
2 Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction Recruiting NCT03388840 Phase 4
3 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
4 Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients Unknown status NCT01655108 Phase 3 Minoxidil;Saline
5 A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia Recruiting NCT03742518 Phase 2, Phase 3 Topical SM04554 solution;Topical SM04554 solution;Topical vehicle solution
6 Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia Completed NCT00958750 Phase 3 minoxidil
7 Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
8 Efficacy and Safety Study to Compare Topical Herbal Solution and Minoxidil 5% in Male Pattern Hair Loss Active, not recruiting NCT03753113 Phase 3 Topical Minoxidil 5%
9 A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
10 A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
11 Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
12 Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111) Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
13 Clinical Trial in Females for Female Pattern Hair Loss Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
14 Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia Completed NCT03004469 Phase 3 P-3074;Finasteride;P-3074 Vehicle;Finasteride Placebo
15 A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Completed NCT00151515 Phase 3 minoxidil
16 Clinical Trial in Females With Female Pattern Hair Loss Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
17 Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
18 Treatment of Androgenetic Alopecia in Males With Theradome™ LH80 PRO Unknown status NCT02528552 Phase 2
19 Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia Unknown status NCT01501617 Phase 1, Phase 2
20 A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia Unknown status NCT01643629 Phase 1, Phase 2
21 Study To Determine Safety & Efficacy Of Autologous Human Platelet Lysate in Androgenetic Alopecia After Hair Transplant Unknown status NCT01644422 Phase 1, Phase 2
22 Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Unknown status NCT00471510 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
23 Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women Unknown status NCT00418249 Phase 2 AS101
24 Efficacy and Safety Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Androgenetic Alopecia Unknown status NCT01650272 Phase 1, Phase 2 5% MInoxidil milky lotion;5% Minoxidil solution
25 Safety and Efficacy of Nitric Oxide Gel in Promoting Hair Growth in Male Human Subjects With Androgenetic Alopecia Unknown status NCT01347957 Phase 1, Phase 2
26 The Effect of Platelet-rich Plasma in Subjects With Androgenetic Alopecia Not yet recruiting NCT03048461 Phase 2 Placebo
27 A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing Completed NCT02503137 Phase 2 Topical SM04554 solution;Topical Vehicle solution
28 A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution Active, not recruiting NCT03495817 Phase 2 ATI-50002
29 Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia Completed NCT01286649 Phase 1, Phase 2
30 A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) Completed NCT02275351 Phase 2 SM04554;Vehicle
31 A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia Completed NCT02279823 Phase 2 CB-03-01 solution;Minoxidil Solution 5%;Placebo solution
32 Adipose Tissue Derived Stem Cell Based Hair Restoration Therapy for Androgenetic Alopecia Completed NCT02865421 Phase 2 stem cells;platelet rich plasma
33 Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia Completed NCT01319370 Phase 2 Minoxidil;vehicle of 5% Minoxidil topical foam
34 Treatment of Male Pattern Baldness With Botulinum Toxin Completed NCT00965640 Phase 2 Botulinum Toxin - A injections
35 Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application Completed NCT02280603 Phase 1, Phase 2 DA-4001C;5% minoxidil
36 A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males Completed NCT02781311 Phase 2 Setipiprant;Placebo;Finasteride
37 Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Completed NCT00418730 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
38 Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss Completed NCT02150187 Phase 2
39 Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia Not yet recruiting NCT03852992 Phase 2 Post-Laser Minoxidil 2%;At-Home Minoxidil 5%;Post-laser 5mg minoxidil;Post-laser 10mg minoxidil;Post-laser 20mg minoxidil
40 Topical Bimatoprost Effect on Androgen Dependent Hair Follicles Completed NCT02170662 Phase 2 Bimatoprost;Placebo
41 Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women Active, not recruiting NCT03488108 Phase 1, Phase 2 Minoxidil Foam
42 STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia Completed NCT02503852 Phase 2
43 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512) Completed NCT01451125 Phase 2
44 A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) Completed NCT01904721 Phase 2 Bimatoprost Solution 1;Bimatoprost Solution 2;Bimatoprost Vehicle
45 Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia Completed NCT01325337 Phase 2 bimatoprost Formulation A;bimatoprost Formulation B;bimatoprost Formulation C;bimatoprost vehicle solution;minoxidil 5% solution
46 A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931) Completed NCT01669746 Phase 2
47 A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995) Completed NCT01451190 Phase 2
48 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669) Completed NCT01451177 Phase 2
49 A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542) Completed NCT01451151 Phase 2
50 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541) Completed NCT01451138 Phase 2

Search NIH Clinical Center for Alopecia, Androgenetic, 1

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Alopecia, Androgenetic, 1 cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Alopecia, Androgenetic, 1:
RepliCel Hair-01 (RCH-01), hair follicle-derived mesenchymal stem cells for treatment of androgenetic alopecia
Embryonic/Adult Cultured Cells Related to Alopecia, Androgenetic, 1:
Hair follicle mesenchymal stem cells (RepliCel Hair-01)

Genetic Tests for Alopecia, Androgenetic, 1

Genetic tests related to Alopecia, Androgenetic, 1:

# Genetic test Affiliating Genes
1 Alopecia, Androgenetic, 1 30

Anatomical Context for Alopecia, Androgenetic, 1

MalaCards organs/tissues related to Alopecia, Androgenetic, 1:

42
Prostate, Testes, Skin, Heart, Breast, Bone, Adipocyte

Publications for Alopecia, Androgenetic, 1

Articles related to Alopecia, Androgenetic, 1:

(show top 50) (show all 650)
# Title Authors Year
1
Evaluation of long-term efficacy of finasteride in Korean men with androgenetic alopecia using the basic and specific classification system. ( 30536893 )
2019
2
Platelet-rich plasma on female androgenetic alopecia: Tested on 10 patients. ( 29707872 )
2019
3
Efficacy and safety of a new 5% minoxidil formulation in male androgenetic alopecia: A randomized, placebo-controlled, double-blind, noninferiority study. ( 29659116 )
2019
4
Insights into Male Androgenetic Alopecia: Differential Gene Expression Profiling of Plucked Hair Follicles and Integration with Genetic Data. ( 30009830 )
2019
5
Controversies in the treatment of androgenetic alopecia: The history of finasteride. ( 30253001 )
2019
6
Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia. ( 30209896 )
2019
7
Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. ( 30206635 )
2019
8
Acne development in male androgenetic alopecia. ( 30499125 )
2019
9
HrQoL in hair loss-affected patients with alopecia areata, androgenetic alopecia and telogen effluvium: the role of personality traits and psychosocial anxiety. ( 30394586 )
2019
10
Platelet-Rich Plasma as a Treatment for Androgenetic Alopecia. ( 30882509 )
2019
11
Letter in response to "The effectiveness of adding low-level light therapy to minoxidil 5% solution in the treatment of patients with androgenetic alopecia". ( 30880717 )
2019
12
Laser-assisted drug delivery for the treatment of androgenetic alopecia: ablative laser fractional photothermolysis to enhance cutaneous topical delivery of platelet-rich plasma - with or without concurrent bimatoprost and/or minoxidil. ( 30865404 )
2019
13
The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. ( 30863034 )
2019
14
Quantitative proteomic analysis of dermal papilla from male androgenetic alopecia comparing before and after treatment with low-level laser therapy. ( 30843235 )
2019
15
Finasteride for androgenetic alopecia is not associated with sexual dysfunction: A survey-based, single-center, controlled study. ( 30835851 )
2019
16
Methods of treatment patients with androgenetic alopecia based on reference of Department of Dermatology in Cracow. ( 30830894 )
2019
17
Platelet-rich plasma for androgenetic alopecia: A review of the literature and proposed treatment protocol. ( 30809579 )
2019
18
The Association of Metabolic Syndrome and Insulin Resistance in Early-Onset Androgenetic Alopecia in Males: A Case-Control Study. ( 30745631 )
2019
19
Prostaglandins in androgenetic alopecia in 12 men and four female. ( 30730082 )
2019
20
Serum biotin and zinc in male androgenetic alopecia. ( 30714301 )
2019
21
PLATELET RICH PLASMA IN ANDROGENETIC ALOPECIA: A SYSTEMATIC REVIEW. ( 30667146 )
2019
22
Efficacy of Off-Label Topical Treatments for the Management of Androgenetic Alopecia: A Review. ( 30652260 )
2019
23
Dickkopf-1 Expression in Androgenetic Alopecia and Alopecia Areata in Male Patients. ( 30640755 )
2019
24
Hair distribution width - a novel trichoscopy parameter for hair miniaturization in androgenetic alopecia. ( 31066933 )
2019
25
Excellent response to mesotherapy as adjunctive treatment in male androgenetic alopecia. ( 31066492 )
2019
26
Photographic assessment improves adherence to recommended follow-up in patients with androgenetic alopecia and alopecia areata: A retrospective cohort study. ( 31062723 )
2019
27
Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia. ( 31054970 )
2019
28
Microbiome in the hair follicle of androgenetic alopecia patients. ( 31050675 )
2019
29
The Higher Number and Longer Duration of Kenogen Hairs Are the Main Cause of the Hair Rarefaction in Androgenetic Alopecia. ( 31049336 )
2019
30
A Study to Compare the Efficacy of Platelet-rich Plasma and Minoxidil Therapy for the Treatment of Androgenetic Alopecia. ( 31007475 )
2019
31
A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia. ( 30982177 )
2019
32
An overview of herbal alternatives in androgenetic alopecia. ( 30980598 )
2019
33
Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. ( 30974011 )
2019
34
Platelet-Rich Plasma and Micrografts Enriched with Autologous Human Follicle Mesenchymal Stem Cells Improve Hair Re-Growth in Androgenetic Alopecia. Biomolecular Pathway Analysis and Clinical Evaluation. ( 30965624 )
2019
35
Androgenetic alopecia and microneedling: Every needling is not microneedling. ( 30905794 )
2019
36
The effect of platelet-rich plasma injection in the treatment of androgenetic alopecia. ( 30895745 )
2019
37
Types of hairline recession in androgenetic alopecia and perceptions of aging in Asian males. ( 30888056 )
2019
38
Gender-specific risk factors for androgenetic alopecia in the Korean general population: Associations with medical comorbidities and general health behaviors. ( 29330930 )
2018
39
Stem cell therapy as a novel therapeutic intervention for resistant cases of alopecia areata and androgenetic alopecia. ( 27553744 )
2018
40
Variation in male sex hormone levels among the pattern subtypes of hair loss in patients with androgenetic alopecia. ( 28266054 )
2018
41
Digit ratio 2D:4D is a possible indicator for androgenetic alopecia in males. ( 28856798 )
2018
42
Original article: Platelet-rich plasma with microneedling in androgenetic alopecia along with dermoscopic pre- and post-treatment evaluation. ( 28771982 )
2018
43
A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia. ( 28604133 )
2018
44
Double-Blind, Placebo-Controlled Pilot Study on the Use of Platelet-Rich Plasma in Women With Female Androgenetic Alopecia. ( 28562436 )
2018
45
Platelet-Rich Plasma in Combination With 5% Minoxidil Topical Solution and 1 mg Oral Finasteride for the Treatment of Androgenetic Alopecia: A Randomized Placebo-Controlled, Double-Blind, Half-Head Study. ( 28562433 )
2018
46
Mediterranean diet: fresh herbs and fresh vegetables decrease the risk of Androgenetic Alopecia in males. ( 29181579 )
2018
47
Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. ( 29178529 )
2018
48
The clinical effect of JetpPeel-assisted topical minoxidil in the treatment of androgenetic alopecia: A randomized pilot study. ( 29166130 )
2018
49
Identification of Functional Patterns of Androgenetic Alopecia Using Transcriptome Profiling in Distinct Locations of Hair Follicles. ( 29122575 )
2018
50
Preservation of stem cells in androgenetic alopecia. ( 29055061 )
2018

Variations for Alopecia, Androgenetic, 1

Expression for Alopecia, Androgenetic, 1

Search GEO for disease gene expression data for Alopecia, Androgenetic, 1.

Pathways for Alopecia, Androgenetic, 1

GO Terms for Alopecia, Androgenetic, 1

Cellular components related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum membrane GO:0005789 9.55 CYP19A1 CYP21A2 SRD5A1 SRD5A2 STS
2 organelle membrane GO:0031090 9.13 CYP21A2 SRD5A1 SRD5A2
3 cell body fiber GO:0070852 8.32 SRD5A1

Biological processes related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.79 AR SRD5A2 TGFB2
2 steroid metabolic process GO:0008202 9.67 CYP21A2 SRD5A1 SRD5A2 STS
3 negative regulation of extrinsic apoptotic signaling pathway GO:2001237 9.61 AR CFLAR
4 cellular response to estradiol stimulus GO:0071392 9.6 CFLAR SRD5A1
5 cellular response to dexamethasone stimulus GO:0071549 9.59 CFLAR SRD5A1
6 sterol metabolic process GO:0016125 9.58 CYP19A1 CYP21A2
7 male genitalia development GO:0030539 9.58 SRD5A1 SRD5A2
8 uterus development GO:0060065 9.57 CYP19A1 TGFB2
9 male gonad development GO:0008584 9.56 AR SRD5A1 SRD5A2 TGFB2
10 androgen biosynthetic process GO:0006702 9.55 SRD5A1 SRD5A2
11 cellular response to testosterone stimulus GO:0071394 9.54 AR SRD5A1
12 prostate gland growth GO:0060736 9.52 AR CYP19A1
13 sex differentiation GO:0007548 9.5 AR SRD5A1 SRD5A2
14 testosterone biosynthetic process GO:0061370 9.49 CYP19A1 SRD5A2
15 androgen catabolic process GO:0006710 9.48 CYP19A1 SRD5A1
16 positive regulation of integrin biosynthetic process GO:0045726 9.43 AR TGFB2
17 response to testosterone GO:0033574 9.4 CFLAR SRD5A1
18 androgen metabolic process GO:0008209 9.33 CYP19A1 SRD5A1 SRD5A2
19 hypothalamus development GO:0021854 9.26 SRD5A1
20 steroid biosynthetic process GO:0006694 9.26 CYP19A1 CYP21A2 SRD5A1 SRD5A2
21 response to follicle-stimulating hormone GO:0032354 9.21 SRD5A1
22 steroid catabolic process GO:0006706 9.16 STS
23 female genitalia development GO:0030540 8.62 CYP19A1 SRD5A1

Molecular functions related to Alopecia, Androgenetic, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.73 CYP19A1 CYP21A2 SRD5A1 SRD5A2
2 steroid hydroxylase activity GO:0008395 9.4 CYP19A1 CYP21A2
3 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.37 SRD5A1 SRD5A2
4 androgen binding GO:0005497 9.32 AR SHBG
5 3-oxo-5-alpha-steroid 4-dehydrogenase activity GO:0003865 9.26 SRD5A1 SRD5A2
6 cholestenone 5-alpha-reductase activity GO:0047751 8.96 SRD5A1 SRD5A2
7 amide binding GO:0033218 8.85 SRD5A1
8 steroid binding GO:0005496 8.8 AR CYP21A2 SHBG

Sources for Alopecia, Androgenetic, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....